PMA SUPPLEMENT BACKLOG GROWTH WILL RETURN, PHILLIPS PREDICTS; PMA PROGRAM DEMONSTRATES CONTINUED RESOURCE SHORTAGE, CDRH SAYS IN BACKGROUND PAPER
This article was originally published in The Gray Sheet
Executive Summary
The backlog of overdue premarket approval application supplements at FDA, which has dropped somewhat over the last three months, will begin to grow again, Philip Phillips, deputy director of the agency's Office of Device Evaluation, said May 4 at the Health Industry Manufacturers Association's Medical Device Software Conference in Washington, D.C.